List of Excipients in Branded Drug MATULANE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Leadiant Biosciences Inc	MATULANE	procarbazine hydrochloride	54482-054	D&C YELLOW NO. 10
Leadiant Biosciences Inc	MATULANE	procarbazine hydrochloride	54482-054	FD&C YELLOW NO. 6
Leadiant Biosciences Inc	MATULANE	procarbazine hydrochloride	54482-054	GELATIN

MATULANE Excipient Strategy and Commercial Opportunities: Procarbazine Formulation, Generic Entry, and Patent Position

Last updated: August 27, 2026

MATULANE is the U.S. brand for procarbazine hydrochloride, an oral alkylating agent used primarily in combination regimens for Hodgkin lymphoma and selected central nervous system tumors. Its commercial opportunity is concentrated in supply reliability, differentiated capsule design, hospital-channel distribution, and lifecycle improvements rather than broad new indications. The core formulation appears relatively simple, which limits conventional excipient patent opportunities but creates room for improvements in stability, swallowability, packaging, and global regulatory harmonization.

What is MATULANE and how is procarbazine used?

MATULANE contains procarbazine hydrochloride in 50-mg capsules. The product is administered orally and is commonly used with other chemotherapy agents, including in the MOPP regimen for Hodgkin lymphoma. The prescribing information includes warnings for myelosuppression, secondary malignancies, central nervous system effects, hepatotoxicity, pulmonary toxicity, and alcohol-related disulfiram-like reactions.[1]

Attribute	MATULANE
Active ingredient	Procarbazine hydrochloride
Strength	50 mg capsule
Dosage form	Immediate-release oral capsule
Primary therapeutic area	Oncology
Principal use	Combination treatment for Hodgkin lymphoma
U.S. NDA	016177
U.S. approval history	Approved before the modern Hatch-Waxman framework
Current commercial positioning	Legacy oncology product with specialized demand
Biologic status	Not applicable
Biosimilar exposure	None

Procarbazine is an older cytotoxic medicine with a narrow, specialized market. Demand is driven by treatment protocols, institutional purchasing, and oncology-center formularies rather than mass retail prescribing.

What excipients are used in MATULANE capsules?

The U.S. prescribing information identifies inactive ingredients in the capsule formulation, including lactose, corn starch, magnesium stearate, and talc. The capsule shell contains gelatin and coloring materials.[1] The exact qualitative and quantitative composition should be confirmed against the current approved labeling and regulatory dossier before development or filing.

Likely functional role of each excipient

Excipient class	Likely function	Commercial and regulatory relevance
Lactose	Diluent and filler	Creates potential for lactose-free differentiation
Corn starch	Filler, disintegrant, processing aid	Conventional and generally cost-efficient
Magnesium stearate	Lubricant	Excessive levels can affect dissolution and content uniformity
Talc	Processing and anti-adherence aid	Requires controlled quality and elemental impurity assessment
Gelatin	Capsule-shell material	Relevant to vegetarian, religious, and supply-chain positioning
Colorants	Product identification and brand recognition	Creates opportunities for dye-free or market-specific variants

The formulation is structurally conventional. Its commercial value does not appear to depend on a complex modified-release system, lipid vehicle, amorphous dispersion, or drug-delivery platform.

What formulation patents protect MATULANE?

Publicly identifiable MATULANE protection is primarily historical and regulatory rather than based on a substantial current U.S. formulation patent estate. Procarbazine hydrochloride is an established active ingredient, and the original product approval predates current patent-listing practices.

The principal constraints are:

1. The active ingredient is old and widely described in the scientific and patent literature.
2. A conventional immediate-release capsule is difficult to protect with broad composition claims.
3. Any new excipient patent would need to distinguish over routine use of fillers, lubricants, capsule shells, stabilizers, and packaging.
4. A patent covering only a generic excipient substitution may have limited commercial value unless it produces measurable stability, dissolution, safety, or manufacturing benefits.

Where new excipient claims could be viable

Potential claim areas include:

• A moisture-controlled capsule formulation that improves procarbazine stability.
• A lactose-free formulation for patients with lactose intolerance or institutions seeking allergen-reduced products.
• A gelatin-free capsule using hypromellose or another non-animal shell.
• A dye-free formulation with equivalent product identification and stability.
• A low-talc or talc-free formulation with improved powder flow and reduced elemental impurity risk.
• A formulation that reduces capsule brittleness, shell cross-linking, or dissolution variability.
• A unit-dose package that improves protection from light, moisture, or occupational exposure.
• A manufacturing process that reduces operator exposure to a cytotoxic active pharmaceutical ingredient.
• A reconstituted or dispersible presentation for patients unable to swallow capsules, subject to toxicology and handling controls.

Patentability would depend on unexpected technical effects. Claims directed only to replacing lactose with another conventional filler or substituting gelatin with hypromellose would face substantial obviousness risk unless supported by comparative data.

How strong is the MATULANE patent estate?

The current estate should be characterized as weak for blocking purposes but potentially useful for product differentiation if new patents are developed around formulation, packaging, or manufacturing.

Protection category	Assessment
Active-ingredient patent	Expired or commercially irrelevant
Original product patent	Historical protection only
Current formulation patents	No major publicly visible U.S. estate identified
Method-of-use patents	Limited practical blocking value for established oncology uses
Manufacturing patents	Potentially available for containment and process controls
Packaging patents	Potentially available for cytotoxic handling and stability
Regulatory exclusivity	No meaningful current new-drug exclusivity expected
Biosimilar protection	Not relevant

The Orange Book is the controlling source for listed patents and exclusivity associated with an approved drug application.[2] A current commercial diligence review should distinguish between patents listed for the reference product and patents held by the brand owner that are not listed because they do not satisfy Orange Book listing requirements.

When does MATULANE lose exclusivity?

MATULANE’s original U.S. regulatory and patent exclusivity expired decades ago. The product is not protected by the five-year new chemical entity exclusivity period available under the Hatch-Waxman Act because its approval predates that framework.

The practical question is therefore not when MATULANE loses exclusivity, but whether a manufacturer can obtain approval and sustain a commercially viable procarbazine capsule product.

Exclusivity type	MATULANE position
New chemical entity exclusivity	Not applicable to the legacy approval
Orphan-drug exclusivity	No current exclusivity identified for the marketed product
Pediatric exclusivity	No current period identified
Patent term extension	No current commercial relevance
Listed formulation patents	No major active estate identified from the core legacy product
Generic approval pathway	Abbreviated or suitability-based pathway may be relevant, subject to FDA requirements

A later patent on a new formulation would protect only the claimed formulation or use. It would not restore exclusivity for the unmodified procarbazine molecule.

What is the FDA regulatory status of MATULANE?

MATULANE is an FDA-approved prescription oncology product. The FDA-approved labeling identifies procarbazine hydrochloride capsules as an oral cytotoxic medicine with substantial handling, dosing, and drug-interaction considerations.[1]

FDA regulatory issues affecting new excipient strategies include:

• Demonstrating pharmaceutical equivalence to the reference product.
• Matching capsule strength and immediate-release performance.
• Establishing bioequivalence where required.
• Controlling impurities, degradation products, and elemental impurities.
• Addressing nitrosamine risk where chemically or process relevant.
• Evaluating excipient safety for chronic or repeated chemotherapy cycles.
• Maintaining adequate warnings for hazardous-drug handling.
• Establishing manufacturing controls for a potent cytotoxic compound.

The FDA’s inactive-ingredient database can help assess precedent for individual excipients and routes of administration, but prior use does not eliminate the need to justify concentration, specification, and formulation performance.[3]

What generic entry risks exist for MATULANE?

Generic entry risk is technically moderate and commercially constrained.

Technical entry risk

A conventional 50-mg immediate-release capsule is generally easier to replicate than a modified-release or biologic product. A prospective generic manufacturer would likely focus on:

• Assay and content uniformity.
• Dissolution equivalence.
• Stability under ICH conditions.
• Capsule-shell compatibility.
• Control of degradation products.
• Containment during blending, encapsulation, and packaging.
• Comparative bioequivalence, if required by FDA.

Commercial entry risk

The small oncology market can deter generic entry even where the technical barrier is low. Manufacturers must account for:

• Low annual unit volumes.
• Specialized oncology distribution.
• Limited prescriber switching.
• Hospital contracting pressure.
• Cytotoxic manufacturing requirements.
• Potential shortages if only one or two suppliers remain.
• Pharmacovigilance and hazardous-drug compliance costs.

Generic launch scenario	Likely commercial effect
One approved generic without reliable supply	Limited price erosion; brand may retain institutional accounts
Multiple approved generics	Greater price pressure and formulary substitution
Authorized generic	Faster erosion with controlled supply and brand-owner economics
Reformulated branded product	Potential retention of premium pricing if clinically useful
Capsule-shell or excipient differentiation only	Limited value unless tied to procurement or patient need

Which companies are challenging MATULANE?

A definitive list of active Paragraph IV challengers requires a current FDA ANDA database and federal litigation search. No major, widely reported Paragraph IV litigation campaign is associated with MATULANE in the principal public oncology patent record.

Because the core product is an old, immediate-release capsule, a challenge would more likely involve approval of a standard generic than a high-value patent dispute. The absence of major reported litigation does not eliminate the possibility of confidential ANDA activity or future abbreviated applications.

Paragraph IV implications

A Paragraph IV certification would matter only if an unexpired patent were listed for the reference product. If no relevant listed patent remains, the principal approval risk would shift from patent litigation to FDA review of pharmaceutical equivalence, bioequivalence, manufacturing, and labeling.

What excipient strategies create commercial opportunities?

1. Lactose-free MATULANE

A lactose-free capsule could address intolerance concerns and simplify procurement for institutions that avoid lactose-containing oral products. The commercial opportunity is likely niche. The formulation must preserve powder flow, fill-weight accuracy, dissolution, stability, and capsule integrity.

A strong development package would compare:

• Assay and content uniformity.
• Dissolution across pH conditions.
• Long-term and accelerated stability.
• Water activity and moisture uptake.
• Capsule brittleness.
• Blend uniformity.
• Bioequivalence or comparative clinical performance.

2. Gelatin-free capsule

A hypromellose capsule could expand use in markets or institutions that restrict animal-derived materials. This option may also reduce dependence on gelatin supply chains. It can introduce changes in moisture transmission, shell behavior, dissolution, and manufacturing speed.

A gelatin-free product is more likely to support a commercial claim than a strong blocking patent unless comparative performance is unexpected.

3. Dye-free or low-allergen presentation

A dye-free product could improve procurement flexibility and reduce concern about colorant sensitivity. The main challenge is maintaining visual differentiation for a hazardous medicine while avoiding medication errors.

Possible solutions include imprinting, opaque shell design, blister geometry, and prominent hazardous-drug labeling.

4. Stability-enhanced packaging

Packaging may provide a more defensible commercial opportunity than routine excipient substitution. Procarbazine is a cytotoxic compound, and packaging must protect the product while controlling occupational exposure.

Potential formats include:

• High-barrier blister packs.
• Unit-dose institutional packaging.
• Child-resistant bottles with containment features.
• Light-protective packaging.
• Moisture-scavenging systems.
• Tamper-evident packaging.
• Packs designed for hazardous-drug handling.

Packaging patents would need claims directed to a specific combination of container, barrier properties, closure, dose presentation, and stability result.

5. Patient-centric oral delivery

Patients receiving chemotherapy may experience nausea, mucositis, fatigue, or swallowing difficulty. A dispersible, liquid, multiparticulate, or orally disintegrating presentation could expand use, but procarbazine’s cytotoxicity creates major handling and exposure concerns.

A liquid product may create higher occupational and caregiver exposure risk than a sealed capsule. A dispersible tablet could face similar concerns unless the dosage form remains contained until administration.

What manufacturing and IP barriers affect MATULANE?

The principal manufacturing barrier is not chemical synthesis. It is safe, reproducible handling of a cytotoxic active ingredient.

A competitive manufacturer would need controls for:

• Closed or contained powder transfer.
• Dedicated or validated equipment.
• Personnel exposure monitoring.
• Cleaning validation.
• Cross-contamination prevention.
• Occupational-health procedures.
• Waste and reject management.
• Specialized packaging and labeling.
• Stability-indicating analytical methods.

These controls can support process patents and trade secrets. A formulation patent may be difficult to enforce if competitors can use a different excipient system. A process patent may be more defensible if it produces a measurable impurity, containment, throughput, or yield advantage, although non-infringing alternative processes can reduce its practical value.

How does MATULANE compare with competing oncology products?

MATULANE differs from newer oral oncology products in both patent intensity and commercial scale.

Product type	Patent intensity	Formulation complexity	Generic or biosimilar threat
MATULANE procarbazine capsule	Low	Low to moderate	Generic competition
Modern oral targeted therapy	High	Moderate to high	Patent and regulatory barriers
Injectable biologic oncology therapy	High	High	Biosimilar competition
Compounded oral chemotherapy	Variable	Variable	Quality and supply concerns
Hospital-administered cytotoxic regimen	Often low at molecule level	Manufacturing and handling intensive	Supplier concentration risk

MATULANE’s advantage is clinical familiarity within established regimens. Its weakness is the absence of strong molecule-level exclusivity and the limited ability to command premium pricing without a meaningful formulation or service improvement.

What licensing deals could support MATULANE growth?

The most practical licensing opportunities involve manufacturing and distribution rather than a conventional discovery collaboration.

Potential counterparties include:

• Specialty generic manufacturers with cytotoxic capacity.
• Contract manufacturers operating contained oral-solid facilities.
• Oncology-focused distributors.
• Hospital-pharmacy suppliers.
• Packaging companies with hazardous-drug containment systems.
• Regional licensees in markets where procarbazine remains protocol-relevant.

A licensing transaction could cover:

• U.S. commercialization rights.
• Regional registration and supply.
• An authorized generic.
• A reformulated lactose-free or gelatin-free product.
• Manufacturing know-how.
• Stability-enhancing packaging.
• Oncology-support services tied to adherence and safe handling.

Royalty economics would likely depend more on supply reliability, geographic access, and cost structure than on broad patent exclusivity.

What revenue exposure does MATULANE represent?

MATULANE revenue is not separately disclosed in the public filings of its commercial owner in a manner that provides a reliable current product-level figure. The product’s exposure is best assessed through market structure rather than headline sales.

Relevant commercial indicators are:

• Number of approved U.S. suppliers.
• Annual procarbazine prescription volume.
• Hospital and specialty-pharmacy purchasing concentration.
• Frequency of oncology drug shortages.
• Average selling price relative to manufacturing cost.
• Share of demand from Hodgkin lymphoma protocols.
• International availability and registration status.
• Substitution behavior after generic launch.

For a specialty product with limited volume, a supply interruption can create a short-term pricing opportunity. That opportunity may not translate into durable revenue because treatment protocols are finite and oncology institutions often seek low-cost alternatives.

What geographic markets offer the best opportunity?

The strongest geographic opportunities are markets with:

• Established Hodgkin lymphoma treatment protocols.
• Limited local supply of procarbazine.
• High reliance on imported oncology medicines.
• Regulatory pathways for well-established medicines.
• Hospital purchasing systems that value dependable supply.
• Demand for animal-free or lactose-free dosage forms.

A single global excipient strategy may not be optimal. Gelatin restrictions, colorant rules, excipient monographs, labeling requirements, and capsule-shell preferences vary by jurisdiction. A modular product platform could use the same procarbazine blend with market-specific capsule shells and packaging.

Key Takeaways

• MATULANE is a legacy 50-mg procarbazine hydrochloride capsule with no meaningful new chemical entity exclusivity remaining.
• Its conventional excipient system limits broad formulation-patent opportunities.
• The best lifecycle opportunities are lactose-free, gelatin-free, dye-free, stability-enhanced, and safer-to-handle presentations.
• Manufacturing containment and packaging are more commercially defensible than routine excipient substitution.
• Generic entry is technically feasible but may be constrained by low market volume and cytotoxic manufacturing requirements.
• A current Orange Book and ANDA review is central to assessing Paragraph IV risk and actual U.S. competition.
• Licensing opportunities are most credible in specialty manufacturing, authorized generics, regional distribution, and differentiated packaging.
• Biosimilar risk is not applicable because procarbazine is a small-molecule drug.

FAQs About MATULANE Excipient and Commercial Strategy

Can a lactose-free MATULANE formulation receive new patent protection?

Yes, but a patent would need more than the substitution of lactose with a conventional filler. Stronger claims would require a defined composition, manufacturing process, or unexpected result such as improved stability, dissolution, or content uniformity.

Is procarbazine a good candidate for an oral liquid formulation?

The therapeutic need may exist, but cytotoxic handling and caregiver-exposure risks make an oral liquid commercially and regulatorily more complex than a sealed capsule or tablet.

Does MATULANE have biosimilar competition?

No. Procarbazine is a small-molecule active ingredient, so competition would arise through generic-drug pathways rather than biosimilar approvals.

Could a hypromellose capsule create a meaningful MATULANE market advantage?

It could support vegetarian, religious, and supply-chain positioning. The commercial advantage would depend on procurement demand and demonstrated equivalent stability and dissolution. The substitution alone would usually provide limited patent strength.

Are manufacturing trade secrets important for procarbazine products?

Yes. Containment, cleaning validation, powder transfer, exposure control, and packaging processes can materially affect cost, supply reliability, and regulatory performance even where the underlying formulation is conventional.

References

1. U.S. Food and Drug Administration. (n.d.). MATULANE (procarbazine hydrochloride) capsules: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA, Center for Drug Evaluation and Research.

4. National Cancer Institute. (n.d.). Procarbazine hydrochloride. National Institutes of Health.

5. U.S. Food and Drug Administration. (2016). Q3D elemental impurities: Guidance for industry. FDA.

6. U.S. Food and Drug Administration. (2024). Hazardous drugs: Handling in healthcare settings. FDA.